Valproic acid stimulates
Cell migration
MSC
immortalized mesenchymal stem cell line (immortalized MSC cell line)
placenta
valproic acid (VPA)
Journal
Stem cell investigation
ISSN: 2306-9759
Titre abrégé: Stem Cell Investig
Pays: China
ID NLM: 101672113
Informations de publication
Date de publication:
2019
2019
Historique:
received:
16
09
2018
accepted:
11
12
2018
entrez:
13
4
2019
pubmed:
13
4
2019
medline:
13
4
2019
Statut:
epublish
Résumé
The placenta is an abundant source of mesenchymal stem/stromal cells (MSC), but our understanding of their functional properties remains limited. We previously created a placental-derived chorionic MSC (CMSC) cell line to overcome the difficulties associated with conducting extensive Stimulators of MSC migration, including two cytokines, stromal cell-derived factor-1α (SDF-1α) and hepatocyte growth factor (HGF), and a pharmacological agent, valproic acid (VPA), were tested for their ability to stimulate CMSC29 cell migration. Assessment of cell migration was performed using the xCELLigence Real-Time Cell Analyzer (RTCA). There was no significant increase in CMSC29 cell migration towards serum free medium with increasing concentration gradients of SDF-1α or HGF. In contrast, treating CMSC29 cells with VPA alone significantly increased their migration towards serum free medium. Immortalized CMSC29 cells retain important properties of primary CMSC, but their migratory properties are altered. CMSC29 cells do not migrate in response to factors that reportedly stimulate primary MSC/CMSC migration. However, CMSC29 increase their migration in response to VPA treatment alone. Further studies are needed to determine the mechanism by which VPA acts alone to stimulate CMSC29 migration. Still, this study provides evidence that VPA pre-treatment may improve the benefits of cell-based therapies that employ certain MSC sub-types.
Sections du résumé
BACKGROUND
BACKGROUND
The placenta is an abundant source of mesenchymal stem/stromal cells (MSC), but our understanding of their functional properties remains limited. We previously created a placental-derived chorionic MSC (CMSC) cell line to overcome the difficulties associated with conducting extensive
METHODS
METHODS
Stimulators of MSC migration, including two cytokines, stromal cell-derived factor-1α (SDF-1α) and hepatocyte growth factor (HGF), and a pharmacological agent, valproic acid (VPA), were tested for their ability to stimulate CMSC29 cell migration. Assessment of cell migration was performed using the xCELLigence Real-Time Cell Analyzer (RTCA).
RESULTS
RESULTS
There was no significant increase in CMSC29 cell migration towards serum free medium with increasing concentration gradients of SDF-1α or HGF. In contrast, treating CMSC29 cells with VPA alone significantly increased their migration towards serum free medium.
CONCLUSIONS
CONCLUSIONS
Immortalized CMSC29 cells retain important properties of primary CMSC, but their migratory properties are altered. CMSC29 cells do not migrate in response to factors that reportedly stimulate primary MSC/CMSC migration. However, CMSC29 increase their migration in response to VPA treatment alone. Further studies are needed to determine the mechanism by which VPA acts alone to stimulate CMSC29 migration. Still, this study provides evidence that VPA pre-treatment may improve the benefits of cell-based therapies that employ certain MSC sub-types.
Identifiants
pubmed: 30976600
doi: 10.21037/sci.2019.01.01
pii: sci-06-2019.01.01
pmc: PMC6414337
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
J Clin Psychiatry. 1999;60 Suppl 2:27-39; discussion 40-1, 113-6
pubmed: 10073385
Eur J Pharmacol. 2001 Apr 13;417(3):169-76
pubmed: 11334847
J Toxicol Clin Toxicol. 2002;40(6):789-801
pubmed: 12475192
Genome Biol. 2003;4(3):207
pubmed: 12620097
Stem Cells. 2004;22(3):405-14
pubmed: 15153617
Stem Cells. 2004;22(3):415-27
pubmed: 15153618
Blood. 2004 Nov 1;104(9):2643-5
pubmed: 15251986
Basic Res Cardiol. 2005 May;100(3):217-23
pubmed: 15754085
Stem Cells Dev. 2005 Jun;14(3):329-36
pubmed: 15969628
Arthritis Rheum. 2009 Mar;60(3):813-23
pubmed: 19248097
Cell Mol Life Sci. 2010 Jan;67(2):295-303
pubmed: 19888551
Int J Cell Biol. 2009;2009:904682
pubmed: 20130773
Neuropsychopharmacology. 2010 Oct;35(11):2225-37
pubmed: 20613717
Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12313-8
pubmed: 21746903
Acta Pharmacol Sin. 2011 Dec;32(12):1433-45
pubmed: 22056617
Exp Cell Res. 2012 Feb 15;318(4):400-7
pubmed: 22166516
Stem Cell Rev. 2013 Feb;9(1):16-31
pubmed: 22628114
Clin Neurosci Res. 2002 Dec;2(3-4):193-212
pubmed: 22707923
Mol Ther. 2012 Oct;20(10):1953-67
pubmed: 22760542
Neurosci Lett. 2012 Sep 27;526(2):100-5
pubmed: 22917608
Physiol Rev. 2012 Oct;92(4):1865-913
pubmed: 23073633
Pharmacol Rev. 2013 Jan 08;65(1):105-42
pubmed: 23300133
Biochem Biophys Res Commun. 2013 Feb 15;431(3):428-32
pubmed: 23333382
J Biol Chem. 2014 Apr 18;289(16):11068-82
pubmed: 24567328
BMC Cell Biol. 2014 May 16;15:15
pubmed: 24885150
Placenta. 2016 Mar;39:134-46
pubmed: 26992686
J Pharmacol Exp Ther. 1996 Mar;276(3):1189-200
pubmed: 8786552
J Pharm Sci. 1996 Apr;85(4):423-6
pubmed: 8901082
J Pharm Sci. 1999 Jan;88(1):142-6
pubmed: 9874716